December 20th 2024.
A major legal firm has taken action against pharmaceutical giant Johnson & Johnson for allegedly selling ineffective cold and flu medicine to Australians. JGA Saddler has filed a class action lawsuit in the Federal Court, targeting the company over their oral cold and flu products sold under the brand names Codral, Sudafed, and Benadryl in the past 18 years.
The firm claims that all of these medications contain phenylephrine, which has been marketed and sold as a decongestant for many years. However, recent evidence in the United States has led the Food and Drugs Administration to consider banning the drug for oral consumption due to its lack of effectiveness.
JGA Saddler is accusing Johnson & Johnson of knowingly selling ineffective products to the Australian public. Director Rebecca Jancauskas explains, "Customers should be able to trust that the medicines they purchase will work as advertised. When they don't, the company responsible should be held accountable." She further adds, "Johnson & Johnson has been manufacturing and marketing a medication that has been proven to be ineffective for decades. They have relied on outdated and flawed studies to sell these products to Australians, misleading them into thinking they will help with congestion."
The class action lawsuit includes a total of 20 Johnson & Johnson products, including 12 Codral products, six Sudafed products, and three Benadryl products. The time frame for eligible purchases is between 2005 and December 2024, and individuals are encouraged to register with the class action at coldandfluclassaction.com.au.
Brisbane ear, nose, and throat specialist Dr. Jo-Lyn McKenzie has spoken out against the unethical actions of corporations selling products they know are ineffective. "It is unconscionable and deeply unethical for companies to continue selling products that they know do not work. This serves as a reminder for Australian consumers to be cautious and well-informed. Instead of relying on direct-to-consumer advertising, it is important to have meaningful conversations with healthcare professionals who can provide evidence-based recommendations."
In conclusion, the class action against Johnson & Johnson seeks to hold the company accountable for misleading and deceiving the Australian public into purchasing ineffective medication. It also serves as a reminder for consumers to be cautious and seek reliable information from healthcare professionals rather than relying on advertisements.
[This article has been trending online recently and has been generated with AI. Your feed is customized.]
[Generative AI is experimental.]
